Laparoscopic interval debulking surgery in advanced ovarian cancer

doi:10.3877/cma.j.issn.1674-6899.2024.06.004

Abstract

Abstract:

Objective

To study the appropriate patient selection and surgical techniques for laparoscopic interval debulking surgery （IDS） after neoadjuvant chemotherapy （NACT） for advanced ovarian cancer.

Methods

The clinical，surgical，pathological and follow-up data were collected from patients with advanced ovarian cancer who met the criteria and underwent laparoscopic IDS after NACT.

Results

From Mar. 2023 to Dec. 2023，six patients underwent laparoscopic IDS after 3 courses of NACT at the department of gynecology，The First Affiliated Hospital of Nanjing Medical University，and all of them achieved R0 resection with a mean operative time of 405 ±42 minutes and intraoperative bleeding of 283 ±194 ml. Two patients were transfused due to preoperative moderate anemia and intraoperative bleeding of more than 400 ml. The median interval between the first postoperative chemotherapy and IDS was 13 days. None of the patients suffered from Clavien-Dindo grade Ⅱor higher complications within 30 days after surgery. After 6 months of follow-up，no patient had recurrence or died.

Conclusions

Laparoscopic IDS allows for the selection of adequately evaluated patients and is performed by an operator with extensive experience in open cytoreduction surgery and good laparoscopic surgical skills，achieving satisfactory tumor reduction while reducing trauma and facilitating postoperative recovery.

Key words: Advanced epithelial ovarian cancer, Neoadjuvant chemotherapy, Laparoscopy, Interval debulking surgery

Chengyan Luo, Lin Yuan, Shulin Zhou, Yi Jiang, Ting Chen, cong Wang, Wenjun Cheng. Laparoscopic interval debulking surgery in advanced ovarian cancer[J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(06): 339-345.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-6899.2024.06.004

https://zhqjwkzz.cma-cmc.com.cn/EN/Y2024/V17/I06/339

Figures/Tables 5

References 25

1	Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2021，71（3）：209-249.
2	Doherty JA，Peres LC，Wang C，et al. Challenges and opportunities in studying the epidemiology of ovarian cancer subtypes［J］. Curr Epidemiol Rep，2017，4（3）：211-220.
3	Lheureux S，Gourley C，Vergote I，et al. Epithelial ovarian cancer［J］. Lancet，2019，393（10177）：1240-1253.
4	Armstrong DK，Alvarez RD，Backes FJ，et al. National Comprehensive Cancer Network（NCCN） clinical practice guidelines in oncology ovarian cancer including fallopian tube cancer and primary peritoneal cancer，Version 1.0，2024. https：/ /www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf.
5	Vergote I，Tropé CG，Amant F，et al. Neoadjuvant chemotherapy or primary surgery in stage ⅢC or Ⅳovarian cancer［J］. N Engl J Med，2010，363（10）：943-953.
6	Fagotti A，Ferrandina MG，Vizzielli G，et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer （SCORPION-NCT01461850）［J］. Int J Gynecol Cancer，2020，30（11）：1657-1664.
7	Kehoe S，Hook J，Nank Ⅳell M，et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer（ CHORUS ）： an open-label，randomised，controlled，noninferiority trial［J］. Lancet，2015，386（9990）：249-257.
8	Onda T，Satoh T，Saito T，et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage Ⅲ/Ⅳovarian，tubal，and peritoneal cancers in a phase Ⅲrandomised trial： Japan Clinical Oncology Group Study JCOG0602［J］. Eur J Cancer，2016，64：22-31.
9	Nagao S，Tamura J，Shibutani T，et al. Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer： GOTIC-019 study［J］. Int J Clin Oncol，2023，28（6）：804-815.
10	Pomel C，Akladios C，Lambaudie E，et al. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy： a phase Ⅱprospective multicenter non-randomized trial （the CILOVE study）［J］. Int J Gynecol Cancer，2021，31（12）：1572-1578.
11	王建六，马丁. 如何看待腹腔镜在妇科恶性肿瘤中的应用［J］.中国妇产科临床杂志，2022，38（3）：161-164.
12	裴丽侠，张国楠. 二氧化碳气腹与妇科恶性肿瘤［J］. 实用妇产科杂志，2022，38（3）：180-182.
13	Suidan RS，Ramirez PT，Sarasohn DM，et al. A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer［J］. Gynecol Oncol，2017，145（1）：27-31.
14	You B，Robelin P，Tod M，et al. CA-125 elimination rate constant K （KELIM） is a marker of chemosensitivity in patients with ovarian cancer： results from the phase ⅡCHIVA trial［J］. Clin Cancer Res，2020，26（17）：4625-4632.
15	Aletti GD，Eisenhauer EL，Santillan A，et al. Identification of patient groups at highest risk from traditional approach to ovarian cancer treatment［J］. Gynecol Oncol，2011，120（1）：23-28.
16	Tozzi R，Ferrari F，Nieuwstad J，et al. Tozzi classification of diaphragmatic surgery in patients with stage ⅢC-Ⅳovarian cancer based on surgical findings and complexity［J］. J Gynecol Oncol，2020，31（2）：e14.
17	Böhm S，Faruqi A，Said I，et al. Chemotherapy response score：development and validation of a system to quantify histopathologic response to neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma［J］. J Clin Oncol，2015，33（22）：2457-2463.
18	Gueli Alletti S，Bottoni C，Fanfani F，et al. Minimally invasive interval debulking surgery in ovarian neoplasm （MISSION trial-NCT02324595）： a feasibility study［J］. Am J Obstet Gynecol，2016，214（4）：503.e1-503.e6.
19	Brown J，Drury L，Crane EK，et al. When less is more： minimally invasive surgery compared with laparotomy for interval debulking after neoadjuvant chemotherapy in women with advanced ovarian cancer［J］. J Minim Invasive Gynecol，2019，26（5）：902-909.
20	Jorgensen K，Melamed A，Wu CF，et al. Minimally invasive interval debulking surgery for advanced ovarian cancer after neoadjuvant chemotherapy［J］. Gynecol Oncol，2023，172：130-137.
21	Zeng S，Yu Y，Cui Y，et al. Efficacy and safety of minimally invasive surgery versus open laparotomy for interval debulking surgery of advanced ovarian cancer after neoadjuvant chemotherapy：a systematic review and a meta-analysis［J］. Front Oncol，2022，12：900256.
22	Nitecki R，Rauh-Hain JA，Melamed A，et al. Laparoscopic cytoreduction after neoadjuvant chemotherapy （LANCE）［J］. Int J Gynecol Cancer，2020，30（9）：1450-1454.
23	Conte C，Rosati A，Marchetti C，et al. Nomogram to predict feasibility of minimally invasive interval debulking surgery in advanced ovarian cancer［J］. Int J Gynecol Cancer，2022，32（4）：532-539.
24	戴岚，狄文. 腹腔镜卵巢癌手术操作的难点和策略［J/CD］. 中华腔镜外科杂志（电子版），2021，14（3）：137-140.
25	张师前，董延磊. 腹腔镜在卵巢癌诊治中需要重视的问题商榷［J/CD］. 中华腔镜外科杂志（电子版），2018，11（2）：77-79.

病例	年龄（岁）	BMI（kg/m²）	FIGO分期	合并症	NACT前Suidan评分	NACT后KELIM评分	手术时间（min）	术中出血（ml）	术中输血（ml）	术后并发症	PFS（月）	OS（月）	结局
1	54	22.1	ⅢC	无	4	1.6	360	100	0	无	12	12	无复发、存活
2	70	21.0	ⅢC	高血压、冠心病	6	1.0	433	200	0	无	11	11	无复发、存活
3	53	23.5	ⅢC	高血压	4	2.0	404	600	1200	无	6	6	无复发、存活
4	59	22.2	ⅢC	糖尿病	5	1.4	379	400	1200	无	6	6	无复发、存活
5	46	21.6	ⅣA	无	4	1.1	384	100	0	无	6	6	无复发、存活
6	61	25.7	ⅣB	高血压	5	1.7	475	300	0	无	4	4	无复发、存活

病例	年龄（岁）	BMI（kg/m²）	FIGO分期	合并症	NACT前Suidan评分	NACT后KELIM评分	手术时间（min）	术中出血（ml）	术中输血（ml）	术后并发症	PFS（月）	OS（月）	结局
1	54	22.1	ⅢC	无	4	1.6	360	100	0	无	12	12	无复发、存活
2	70	21.0	ⅢC	高血压、冠心病	6	1.0	433	200	0	无	11	11	无复发、存活
3	53	23.5	ⅢC	高血压	4	2.0	404	600	1200	无	6	6	无复发、存活
4	59	22.2	ⅢC	糖尿病	5	1.4	379	400	1200	无	6	6	无复发、存活
5	46	21.6	ⅣA	无	4	1.1	384	100	0	无	6	6	无复发、存活
6	61	25.7	ⅣB	高血压	5	1.7	475	300	0	无	4	4	无复发、存活

[1]	Wei Hong, Xirong Ye, Zhihong Liu, Yinfeng Yang, Zhihong Lyu. Value of ultrasound radiomics combined with clinicopathological features in predicting complete pathological response to neoadjuvant chemotherapy for breast cancer [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(06): 571-579.
[2]	Zhenning Wang, Kang Yang, Dechen Wang, Min Zou, Mingbin Gui, Yanan Wang, Ming Xu. Comparison of long-term therapeutic effects in patients with middle and low rectal cancer using robot-assisted laparoscopy combined with natural orifice specimen extraction [J]. Chinese Archives of General Surgery(Electronic Edition), 2024, 18(06): 437-442.
[3]	Dean Mu, Kai Li, Zhiyuan Zhang, Wei Zhang. Ultramicroscopic instrument assisted single hole laparoscopic partial splenectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 14-14.
[4]	Liuqing Li, Xiaoxiang Chen, Chengyu Lv. Comparison of total laparoscopic and laparoscopic assisted radical gastrectomy in the treatment of advanced gastric cancer in the near and medium term [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 23-26.
[5]	Baoxiong Zhuang, Haijun Deng. Single-incision plus one-port laparoscopic lateral lymph node dissection for rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 601-601.
[6]	Jie Xu, Yajun Li, Yiwen Feng. Comparison of recent follow-up between laparoscopic D2 radical surgery and conventional radical surgery for advanced gastric cancer after SOX neoadjuvant chemotherapy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 647-650.
[7]	Mingyang Pang, Yong Wei, Luming Shen, Qingyi Zhu. Domestic single port robot-assisted laparoscopic partial cystectomy via pneumatic bladder approach for bladder cancer: a case report [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 638-643.
[8]	Haoyuan Wang, Haiyang Wang, Jianming Sun, Yikuan Chen, Xiaotong Qi, Bo Tang. Comparison of laparoscopic and open surgery on early postoperative liver function and coagulation function in patients with abdominal external hernia and cirrhosis [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 654-659.
[9]	Zhengyang Zhou, Kai Chen, Duoliang Qiu, Lening Shao, Haorong Wu, Fengyun Zhong. Analysis and management of postoperative hemorrhage following laparoscopic inguinal hernia repair [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2024, 18(06): 660-664.
[10]	Chaobo Chen, Decai Yu. Key points，lines，and planes for laparoscopic anatomical liver resection [J]. Chinese Journal of Laparoscopic Surgery(Electronic Edition), 2024, 17(06): 321-328.
[11]	Hao Zhang, Weidong Pan. Current status and progress in assessment of resectability of pancreatic cancer after neoadjuvant chemotherapy [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 629-633.
[12]	Junhua Wang, Ruixuan Wang. Current status and treatment strategy of neoadjuvant chemotherapy for pancreatic cancer [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(05): 640-643.
[13]	Jiagang Han, Zhenjun Wang. The treatment strategies for obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 450-458.
[14]	Yang Shi, Jianfeng Yu, Ke Cao, Zhiwei Zhai, Chunxiang Ye, Zhenjun Wang, Jiagang Han. Perioperative complication analysis of self-expanding metallic stents （sems） combined with neoadjuvant chemotherapy in the treatment of complete obstructive left-sided colon cancer [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 464-471.
[15]	Xuanhao Liang, Xiaorong Li, Liang Li, Changwei Lin. Efficacy and prognosis of colonic stenting combined with neoadjuvant chemotherapy for acute obstructive colorectal cancer： a Meta-analysis [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(06): 472-482.

Please choose a citation manager

Content to export